Cavinton, tablets 5 mg 50 pcs

A drug that improves cerebral blood circulation and brain metabolism.

Increases glucose and oxygen consumption by brain tissue.

Enhances neuronal resistance to hypoxia; by enhancing glucose transport to the brain through the BBB; shifts glucose breakdown to a more energy-efficient, aerobic pathway; selectively blocks Ca2+-dependent phosphodiesterase; increases brain AMP and cGMP levels. Increases ATP concentration in brain tissues; enhances brain noradrenaline and serotonin metabolism; stimulates ascending branch of noradrenergic system, has antioxidant effect.

Decreases platelet aggregation and increased blood viscosity; increases the deformability of red blood cells and blocks red blood cell utilization of adenosine; promotes oxygenation of red blood cells.

It enhances the neuroprotective effect of adenosine. Increases cerebral blood flow; decreases cerebral vascular resistance without significant changes in indicators of systemic circulation (BP, minute volume, HR, total peripheral resistance).

Not only does not have the effect of “stealing” but also increases the blood supply, especially in the ischemic areas of the brain with low perfusion.

Indications

Ophthalmology: chronic vascular diseases of the vasculature and retina.

To treat perceptual hearing loss, Meniere’s disease, idiopathic tinnitus.

Neurology: to reduce the severity of neurological and psychiatric symptoms in various forms of cerebral circulatory insufficiency.

Active ingredient

Composition

Active substance:

Vinpocetine 5 mg.

How to take, the dosage

Ingestion, after meals. Usually the daily dose is 5-10 mg 3 times a day (15-30 mg per day). The initial daily dose is 15 mg. Maximum daily dose is 30 mg. The therapeutic effect develops approximately one week after starting to take the drug. The course of treatment is 1-3 months.

In case of kidney and liver diseases the drug is prescribed in the usual dose; the absence of cumulation allows long courses of treatment.

Interaction

It is not observed when concomitant use with pindolol, clopamide, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide; imipramine.

In rare cases, concomitant use with α-methyldopa is accompanied by some increase in the hypotensive effect, and regular BP control is required with this combination.

While there is no data to support the possibility of interaction, caution is recommended when concomitant administration with drugs of central, antiarrhythmic and anticoagulant action.

Special Instructions

Cavinton does not have hepato- and nephrotoxic effects, so when prescribing the drug to patients with liver and kidney disease dosage regimen adjustment is not required.

In case of lactose intolerance, note that each tablet contains 83 mg of lactose.

Pediatric use

The drug is not recommended for children under the age of 18 years because of the lack of experience in using Cavinton in this category of patients.

Contraindications

The acute phase of hemorrhagic stroke; severe CHD; severe arrhythmias; pregnancy; lactation; children under 18 years of age (due to insufficient data); lactose intolerance; hypersensitivity to vinpocetine.

Side effects

Adverse events during the use of the drug were rare.

Cardiovascular system disorders: ECG changes (ST depression, QT interval prolongation); tachycardia, extrasystole, but the causal relationship is not proved, because in natural population these symptoms are observed with the same frequency; BP changes (often decrease), skin hyperemia, phlebitis.

CNS disorders: sleep disorders (insomnia, increased sleepiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease).

Digestive system disorders: dry mouth, nausea, heartburn. Other: allergic skin reactions; increased sweating.

Overdose

There are currently limited data on vinpocetine overdose.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

It is contraindicated in pregnancy. Vinpocetine penetrates the placental barrier.

In this case its concentration in the placenta and fetal blood is lower than in the blood of the pregnant woman.

In high doses placental bleeding and spontaneous abortions are possible, probably as a result of increased placental blood supply.

In one hour, 0.25% of the administered dose of the drug penetrates into the breast milk.

Breastfeeding should be stopped when using the drug.

Similarities